Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy for breast cancer: a case report
Authors:
Open Access
- 14 January 2021
- journal article
- case report
- Published by Springer Nature in Surgical Case Reports
- Vol. 7 (1) , 1-5
Abstract
Background: With the introduction of dose-dense therapy, the use of primary pegfilgrastim (PEG-G) has been increasing in breast cancer treatment. A rare side effect of PEG-G is aortitis. We describe a case of PEG-G-induced aortitis. Case presentation: The patient was a 43-year-old woman with stage IIA breast cancer. Due to the subtype of triple-negative breast cancer, preoperative dose-dense epirubicin–cyclophosphamide chemotherapy was started. PEG-G was administered on day 3 after the first cycle of epirubicin–cyclophosphamide chemotherapy. On day 11, she had a fever (39.4 °C) and an elevated C-reactive protein level (27.1 mg/dL). Emergency computed tomography revealed diffused wall thickening of the aortic arch without any other signs of infection. Despite administering antibiotics, her general condition and laboratory findings deteriorated until day 18. Based on these observations, she was diagnosed with PEG-G-induced aortitis. Antibiotics were discontinued, and she was treated with prednisolone thereafter. Subsequently, her clinical symptoms and laboratory findings improved around day 39. A second computed tomography scan revealed a decrease in the aortic arch wall thickening, and she was discharged on day 43. Conclusions: We successfully treated PEG-G-induced aortitis using prednisolone. Although this side effect is rare, cancer patients receiving PEG-G for chemotherapy should be monitored for aortic inflammation.Keywords
This publication has 16 references indexed in Scilit:
- Mesenteric vasculitis after G-CSF administration in a severe neutropenic patient with systemic lupus erythematosusLupus, 2016
- A case of an SLE patient with febrile neutropenia who experienced exacerbation of cutaneous manifestations after the administration of G-CSFModern Rheumatology, 2013
- Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsCochrane Database of Systematic Reviews, 2012
- A case of an SLE patient with febrile neutropenia who experienced exacerbation of cutaneous manifestations after the administration of G-CSFModern Rheumatology, 2012
- Changes of cytokine levels during granulocyte–colony‐stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significanceTransfusion, 2010
- Review article: Drug‐induced anti‐neutrophil cytoplasmic antibody‐associated vasculitisNephrology, 2009
- Fulminant Vasculitis: A Rare Fatal Complication of LymphomaActa Haematologica, 2006
- Aortite après injections de G-CSFLa Revue de Médecine Interne, 2004
- Drug-induced vasculitisExpert Opinion on Drug Safety, 2003
- Cutaneous and Systemic Manifestations of Drug-Induced VasculitisAnnals of Pharmacotherapy, 2002